Get the Stockscreener App
22.05
3.86%
0.82
Arcus Biosciences Inc stock is traded at $22.05, with a volume of 2.03M.
It is up +3.86% in the last 24 hours and up +22.16% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$21.23
Open:
$21.19
24h Volume:
2.03M
Relative Volume:
1.57
Market Cap:
$2.38B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-7.1359
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+9.87%
1M Performance:
+22.16%
6M Performance:
+156.10%
1Y Performance:
+54.41%
1-Day Range:
$20.82
$22.49
1-Week Range:
$19.44
$22.49
52-Week Range:
$6.50
$22.49
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
22.05 | 2.63B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences stock hits 52-week high at 22.13 USD By Investing.com - Investing.com Nigeria
What is the fair value estimate for Arcus Biosciences Inc. stock in 2025Portfolio Update Report & Stepwise Entry/Exit Trade Alerts - newser.com
How Arcus Biosciences Inc. stock benefits from digital adoptionRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Is Arcus Biosciences Inc. stock vulnerable to rate hikesWeekly Stock Report & Technical Analysis for Trade Confirmation - newser.com
Is Arcus Biosciences Inc. stock positioned for digital transformationJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com
Arcus Biosciences (NYSE:RCUS) NYSE Composite Shows Biotech Energy - Kalkine Media
Will Arcus Biosciences Inc. stock benefit from automation2025 Momentum Check & Smart Money Movement Tracker - newser.com
How strong dollar benefits Arcus Biosciences Inc. stockQuarterly Performance Summary & Reliable Volume Spike Trade Alerts - newser.com
How dovish Fed policy supports Arcus Biosciences Inc. stock2025 Trade Ideas & Weekly Watchlist for Hot Stocks - newser.com
Is Arcus Biosciences Inc. stock cheap by valuation metrics2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Will Arcus Biosciences Inc. stock recover faster than industryWeekly Profit Analysis & Reliable Breakout Stock Forecasts - newser.com
Can Arcus Biosciences Inc. stock deliver strong Q4 earningsOptions Play & High Accuracy Trade Signal Alerts - newser.com
Is Arcus Biosciences Inc. stock a buy on dips2025 Big Picture & Safe Entry Zone Identification - newser.com
Does Arcus Biosciences Inc. show high probability of rebound2025 Top Gainers & Reliable Volume Spike Trade Alerts - newser.com
What downside risks could hit Arcus Biosciences Inc. stockTrade Analysis Summary & Free High Return Stock Watch Alerts - newser.com
Arcus Biosciences Opens with 8.22% Gain, Contrasting S&P 500's Decline - Markets Mojo
Arcus Biosciences (NYSE: RCUS) to Present at Evercore and Citi Healthcare Conferences - Stock Titan
Madison Square Garden Sports Corp MS8 Stock Analysis and ForecastStock Watchlist Updates & Minimal Capital Growth Ideas - earlytimes.in
Shareholder Jaen Juan Carlos & Anita Galeana 2000 Trust Files To Sell 50,000 Of Arcus Biosciences Inc [RCUS] - TradingView
[144] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Can Arcus Biosciences Inc. stock ride next bull market cycle - newser.com
How Arcus Biosciences Inc. stock reacts to job market dataWall Street Watch & Community Verified Swing Trade Signals - newser.com
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):